Actinium Pharmaceuticals, Inc. Provides Mid-Year Update Directed At Existing And Future Shareholders

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

NEW YORK--(BUSINESS WIRE)--Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today provided a Mid-Year Corporate Update to new and existing shareholders. The highlights below underscore the significant progress that the Company has achieved on all material fronts this year which leave it well positioned to execute on its business plan and capitalize on the near-term promise of its core product candidates Iomabâ„¢-B and Actimab-A.

Help employers find you! Check out all the jobs and post your resume.

Back to news